Medications for Anxiety with Least Impact on QTc Interval

Understanding QTc Prolongation Risk Among Anxiety Medications

Citalopram and escitalopram have been associated with dose-related QTc prolongation, with citalopram having FDA warnings about QTc prolongation at doses exceeding 40 mg/day, and may cause QT prolongation associated with Torsade de Pointes, ventricular tachycardia, and sudden death at higher doses, according to the American Academy of Child and Adolescent Psychiatry 1
Benzodiazepines have not been associated with clinically significant QTc prolongation in clinical use, and in vitro studies have shown both inhibition and activation of potassium currents during benzodiazepine exposure, but no changes in QT duration have been reported in clinical practice, as reported by the European Heart Journal 2

Benzodiazepines show no significant QTc prolongation in clinical use and can be considered safe options from a cardiac perspective, according to the European Heart Journal 2
Tricyclic antidepressants (TCAs) have been associated with increased risk of cardiac arrest (OR 1.69) and should be avoided when QTc prolongation is a concern, as reported by the European Heart Journal 2

Consider baseline QTc interval before initiating any psychotropic medication, and evaluate for other risk factors such as electrolyte abnormalities, concomitant QT-prolonging medications, or structural heart disease, as recommended by the European Heart Journal 3
Elderly patients (>60 years) are at higher risk and require more cautious dosing, according to the European Heart Journal 2

Obtain baseline ECG before initiating treatment with any medication that has potential QTc effects, and follow-up ECG monitoring during dose titration is recommended for medications with known QTc effects, as recommended by the European Heart Journal 3
Avoid concomitant use of multiple medications that can prolong the QT interval, as recommended by the European Heart Journal 3

For patients with cardiac disease or risk factors for QTc prolongation, consider benzodiazepines for short-term management, and avoid citalopram, escitalopram, and TCAs, as recommended by the Journal of the American Academy of Child and Adolescent Psychiatry and the European Heart Journal 1, 2
For patients on multiple medications, choose paroxetine or sertraline due to lower risk of drug interactions, and avoid fluvoxamine due to multiple CYP450 interactions, as recommended by the Journal of the American Academy of Child and Adolescent Psychiatry 1
Monitor closely if combination therapy is necessary, as recommended by the European Heart Journal 3